SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside

• The event-driven study had 72 events recorded as of Dec. 26, 2025, nearing the 80 events required to trigger the final survival analysis.
• Maxim said that although top-line data had been expected by the end of 2025, delays in reaching the event threshold in survival-based trials may reflect longer patient survival.
• Koyfin consensus shows an average price target of $6.83, implying about 29% potential gains from current levels. 

Shares of Sellas Life Sciences Group Inc. (SLS) jumped to over a three-year high on Monday as investors await the final readout of its late-stage acute myeloid leukemia (AML) therapy, with analysts signaling the delayed event timing could indicate stronger survival outcomes.

SLS stock has finished in the green in 11 of the last 12 sessions, gaining more than 5% on Tuesday to close at $5.31.

Phase 3 AML Trial Nears Key Event Trigger

The rally comes as the company’s Phase 3 Regal study evaluating Galinpepimut-S (GPS) in AML approaches the event threshold required to trigger the final analysis. The stock has surged ahead of the potential data catalyst, gaining more than 100% during December alone.

Sellas said in late December that the contract research organization overseeing the Regal trial reported 72 events as of Dec. 26, 2025, placing the study close to the 80 events required to initiate the final analysis. 

The trial is testing GPS as a maintenance treatment for AML patients whose cancer returned but went back into remission after additional therapy. The study’s main goal is to see whether the drug helps patients live longer.

Since the trial is event-driven, the timing of the final readout depends on the time of the 80th event. The company said it will announce the milestone once it is reached. Sellas also noted that it remains fully blinded to the efficacy and survival outcomes.

Once the 80-event threshold is reached, the study will be unblinded and analyzed to determine whether the therapy improves survival outcomes for AML patients.

Analysts See Delay As Potentially Positive Signal

After the December update on the Regal trial by Sellas, Maxim said that “in any clinical trial, pinpointing the timing of events and survival timelines is challenging.”

The brokerage said that while top-line data had been expected by the end of 2025, delays in event-driven studies like Regal can sometimes indicate longer survival among patients, though the firm noted the results remain fully blinded and it is too early to draw conclusions.

Wall Street Sees Further Upside

Despite the recent rally, analysts still see additional upside potential. According to Koyfin consensus estimates, the stock carries an average 12-month price target of $6.83, implying a 29% upside from current levels. 

Analyst sentiment remains positive, with one 'Buy' rating and two 'Hold' ratings among covering analysts, while the average analyst rating stands at 'Strong Buy' on a five-point scale.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment for SLS was ‘extremely bullish’, with message volume rising 47% over the past 24 hours. Activity on the platform has also surged more than 1,000% over the past month.

One user said, “Just a reminder that there are 99.99% chances of success for REGAL. Failure is a statistical impossibility.”

Another user noted, “Nice steady climb on decent volume. A PR Friday morning would be epic.”

SLS stock has risen 41% year-to-date.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on